Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
Stocks Mixed After Fed Decision, Jobs Data
Mario Veneroso, partner & wealth manager with Kingsview Asset Management, joined Cheddar News to discuss Monday's trading session following last week's Fed decision to hike rates as well as Friday's jobs data.
Load More